TYKERB (Lapatinib)

TYKERB (Lapatinib)

Regular price
$2,331.99 USD
Sale price
$2,331.99 USD
Regular price
Sold out
Unit price
Shipping calculated at checkout.


What is this medication?

TYKERB (Lapatinib)
Antineoplastic Agent, Anti-HER2; Epidermal Growth Factor Receptor (EGFR) Inhibitor; Tyrosine Kinase Inhibitor

TYKERB (Lapatinib), a kinase inhibitor, is indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. TYKERB is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor.

Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain.

How does this medication work? 

TYKERB (Lapatinib) passes through the cell membrane and binds to HER2, blocking the HER2 signaling cascade associated with cell proliferation and tumor growth.  Combination therapy with lapatinib and endocrine therapy may overcome endocrine resistance occurring in HER2+ and hormone receptor positive disease.

How should I take this medication? 

Oral: Take 1000mg to 1500mg once daily.

How to Take: Administer on an empty stomach, 1 hour before or 1 hour after a meal. Administer the full dose once a day (tablets administered all at once); dividing dose throughout the day is not recommended.

What should I watch for while using this medication?

Before using TYKERB (Lapatinib), make sure your physician is aware of any allergies or medications you currently take, pre-existing medical conditions and activities you perform. Lapatinib has been reported to cause cardiotoxicity, seen by a decrease in left ventricular ejection fraction (LVEF) usually within the first 3 months of treatment; baseline and periodic LVEF evaluations are recommended. Severe cutaneous reactions have been reported with use. Diarrhea is common (onset is generally within 6 days and duration is 4 to 5 days); may be severe and/or fatal. Diarrhea is best managed with early intervention; instruct patients to immediately report any bowel pattern changes.  Hepatotoxicity has been observed in clinical trials and post-marketing experience. Pulmonary toxicity: Interstitial lung disease (ILD) and pneumonitis have been reported (with lapatinib monotherapy and combination chemotherapy).  Concentration-dependent QT prolongation has been observed with Lapatinib. Lapatinib has been used with caution in patients with hepatic impairment.

What if I miss a dose?

If you miss a dose of medication, resume with the next scheduled daily dose; do not double the dose the next day.

How should I store this medication?

Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed.  Properly dispose of any unused medication after the expiration date.

What are the possible side effects of using this medication? 

Fatigue, headache, palmar-plantar erythrodysesthesia (with capecitabine), skin rash, alopecia, xeroderma, pruritus, nail disease, diarrhea, nausea, vomiting, mucositis, stomatitis, anorexia, dyspepsia, decreased hemoglobin (with capecitabine), decreased neutrophils (with capecitabine), decreased platelet count (with capecitabine), increased serum aspartate aminotransferase, increased serum alanine aminotransferase, increased serum bilirubin, asthenia, limb pain, back pain, dyspnea, epistaxis, insomnia.

Note this is not a complete list of side effects for TYKERB (Lapatinib), only common ones.